Medtronic, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Medtronic Vascular, Inc.

The United States of America

Marc Hendriks

Michel L Verhoeven

Patrick T Cahalan

Linda L Cahalan

Benedicte Fouache

Jean A Woloszko

Larry K Keefer

Peiwen Cheng

Antoine N Camps

Robert L Cafferata

Eugene Tedeschi

Mark W Torrianni

Fredric W Lindemans

Ursula Gebhardt

Joseph Saavedra

Anthony L Fitzhugh

Mirian Gillissen

William Jeffrey Bertrand

Vincent Larik

Edouard A Koullick

Edze Jan Tijsma

Edouard Koulik

Leo J Kretzers

Berthold Kramm

Michel I P M Verhoeven

Theo Lindhout

Kuno M&uuml;nch

Ron Blezer

Frank Van Wijk

Michel L P M Verhoeven

Verhoeven Michel

Benedict Fouache

Piet Dijkstra

Raymond Zeeman

Jan Feijen

Anita Driessen-Levels

Benedicte Foache

Frank Everaerts

Medical devices and methods for reducing localized fibrosis at the site of the medical device.

Medical devices and methods for reducing localized fibrosis

An occlusion resistant medical shunt, particularly a hydrocephalic shunt, is provided for implantation into a mammal. The shunt has an elongate wall structure configured as a tube having a lumen therethrough and a proximal end for receipt of bodily fluids. The bodily fluids, such as cerebrospinal fluid, flows through the shunt to a distal end for discharge of the bodily fluids. The wall structure of the shunt generally includes a biocompatible medical device material. The shunts of the present invention further include one or more occlusion resistant materials to resist occlusion of the lumenal passage in the shunt.

Occlusion resistant hydrocephalic shunt

Medical devices with polymer coatings designed to control the release of angiotensin-(1-7) receptor agonists from medical devices are disclosed. The present application also discloses providing vascular stents with angiotensin-(1-7) receptor agonist-containing controlled-release coatings. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients are also provided.

Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function

Methods for making crosslinked material, such as collagen-based material, and bioprosthetic devices. The crosslinked material includes hydroxyl groups, carboxyl groups, and amine groups prior to crosslinking. The methods include removing at least a portion of the zero-length ester crosslinks in a crosslinked material and/or blocking at least a portion of the amine groups that are reactive with carboxyl groups and form zero-length crosslinks.

Methods of preparing crosslinked materials and bioprosthetic devices

Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Nitric oxide-releasing metallic medical devices

The present invention provides a medical device that includes a carrier and a polynucleotide, where the carrier has a surface that includes a polymer with which the polynucleotide is associated. In another aspect, the present invention provides a medical device that includes a carrier and a cell that expresses an antimicrobial peptide, where the carrier has a surface that includes a polymer with which the cell is associated. The present invention further provides methods of making and using medical devices that include a carrier and a polynucleotide or a cell.

Medical device and methods of use

A method of making a temporary medical electrical lead for pacing or defibrillating a heart of a patient. The method comprises providing at least one electrical conductor having proximal and distal ends; providing an insulating sheath formed of biocompatible material extending over and covering at least portions of the at least one electrical conductor, attaching an electrical connector assembly to the proximal end of the at least one electrical conductor for attachment to a device capable of providing pacing or defibrillation pulses; providing an electrode mounting pad in the form of a cast matrix structure made of a biodegradable, biocompatible material soluble in human body fluids and having an outer heart non-contacting surface and an inner heart contacting surface, the outer surface being less permeable to passage of body fluids than the inner surface and wherein the inner surface of the pad has larger interstices and is less dense than the outer surface; providing a drug for treating for treating a medical condition of the patient's heart; loading the drug into the matrix of the pad; and attaching at least portions of the distal end of the at least one electrical conductor or of the electrode member to the electrode mounting pad.

Method of making a temporary medical lead having biodegradable electrode mounting pad loaded with therapeutic drug

An implantable device for reducing restenosis includes a structure including a polyamino acid component, wherein the polyamino acid component can be in the form of a coating or a film on the structure or it can be an integral part of the structure.

Implatable device including a polyamino acid component

A temporary cardiac electrical stimulating lead is disclosed having a stimulating electrode mounted in or on an electrode mounting pad disposed at a distal end of the lead, the pad having a biodegradable adhesive disposed thereon and/or therewithin. The adhesive, and preferably also the electrode mounting pad, are capable of biodegradably dissolving over time in human body fluids. The adhesive permits the electrode mounting pad to be attached to a patient's epicardium without the use of sutures, or with fewer sutures than have heretofore been required to suitably affix an electrode mounting pad to a patient's heart. In a preferred embodiment, when the lead body is pulled away from the electrode mounting pad and removed from a patient, any portion of the electrode mounting pad and the adhesive remaining within the patient dissolves over time and disappears.

Temporary medical electrical lead having electrode mounting pad with biodegradable adhesive

A temporary cardiac electrical stimulating lead comprises a stimulating electrode mounted in or on a biodegradable electrode mounting pad disposed at a distal end of the lead. The electrode mounting pad is capable of biodegradably dissolving over time in human body fluids and is loaded with a drug for therapeutically treating a medical condition of a patient's heart. The electrode mounting pad may be loaded with any of a variety of different drugs, such anti-arrhythmia or anti-inflammatory drugs. When the lead body is pulled away from the electrode mounting pad and removed from the patient, any portion of the electrode mounting pad remaining within the patient dissolves over time and disappears.

Temporary medical electrical lead having biodegradable electrode mounting pad loaded with therapeutic drug

A temporary cardiac electrical stimulating lead is disclosed where the lead body thereof may be removed from inside a patient through the application of a simple pulling force exerted on its proximal end. An electrode mounting pad is located at the distal end of the lead and has a stimulating electrode mounted thereon or therein. A distal end of the electrical conductor may serve as the stimulating electrode. The electrode mounting pad is preferably capable of biodegradably dissolving or otherwise dissociating over time in human body fluids. Thus, the lead body may be detached from the electrode mounting pad through the application of a simple pulling force and removed from the patient while the electrode mounting pad remains within the patient and dissolves or otherwise dissociates over time.

Temporary medical electrical lead having biodegradable electrode mounting pad

Methods for making bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided. The methods include blocking at least a portion of the collagen amine groups with a blocking agent, activating at least a portion of the collagen carboxyl groups after blocking at least a portion of the collagen amine groups to form activated carboxyl groups, and contacting the activated collagen carboxyl groups with a polyfunctional spacer to crosslink the collagen-based material.

Process for making a bioprosthetic device

Bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided as well as methods for their formation. The methods comprise combining an epoxy functionalized crosslinking agent with the collagen-based material in an aqueous medium at an acidic pH to react a portion of the collagen carboxyl groups with the epoxy functionalized crosslinking agent to form crosslinked collagen-based material comprising residual collagen carboxyl groups.

Process for making a bioprosthetic device and implants produced therefrom

A method for making a medical device having a biomolecule immobilized on a substrate surface is provided. The method includes coating the substrate surface with an amino-functional polysiloxane; and contacting the amino-functional polysiloxane coated surface with a biomolecule under conditions effective to immobilize the biomolecule.

Method for attachment of biomolecules to surfaces of medical devices

Growing community of inventors

Brunssum, Netherlands

Marc Hendriks